Solid Biosciences (NASDAQ:SLDB) Issues Earnings Results, Misses Expectations By $0.12 EPS

Solid Biosciences (NASDAQ:SLDB) posted its quarterly earnings data on Wednesday. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.12), Zacks reports.

Solid Biosciences Trading Down 6.0 %

SLDB stock opened at $5.77 on Friday. Solid Biosciences has a 12 month low of $2.00 and a 12 month high of $15.05. The firm has a 50-day moving average of $6.91 and a two-hundred day moving average of $7.78.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on SLDB shares. Barclays reduced their target price on shares of Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a research report on Thursday. William Blair raised shares of Solid Biosciences to a “strong-buy” rating in a report on Friday, August 30th. Finally, JPMorgan Chase & Co. raised shares of Solid Biosciences from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $10.00 to $15.00 in a report on Monday, July 15th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Solid Biosciences presently has an average rating of “Buy” and an average target price of $15.67.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.